GALT's Belapectin Shows Promise in MASH Cirrhosis, Varices Reduced

TL;DR

**GALT's belapectin showed a significant reduction in varices in MASH cirrhosis for compliant patients and in the US, making it a speculative buy on subgroup data despite missing the primary endpoint.**

AI Summary

GALECTIN THERAPEUTICS INC. (GALT) reported top-line results for its NAVIGATE Phase 2b/3 clinical trial in December 2024, evaluating belapectin for the prevention of esophageal varices in MASH cirrhosis patients. While the composite endpoint in the intent-to-treat (ITT) population (N=355) did not reach statistical significance, the belapectin 2 mg/kg dose group showed a 43.2% reduced incidence of varices versus placebo. In the pre-defined per-protocol population (PPP, n=287), the 2 mg/kg dose reduced varices incidence by 49.3% (p-value < 0.05). Notably, U.S. patients (n=186) treated with belapectin 2 mg experienced a significant 68.1% reduction in varices (p=0.02). Belapectin also demonstrated consistent, meaningful effects across multiple key biomarkers, including reduced liver stiffness (LSM) and improved ELF scores, particularly in high-risk subgroups. The safety profile remained highly encouraging, with adverse events and serious adverse events comparable to placebo, and no drug-related SAEs reported. The company is also pursuing a Phase 2 trial for advanced or metastatic head and neck cancer using belapectin in combination with a PD-1 inhibitor, contingent on financing.

Why It Matters

GALECTIN THERAPEUTICS' belapectin, despite missing its primary endpoint in the ITT population, demonstrated statistically significant varices reduction in the per-protocol and U.S. patient subgroups, offering a potential new treatment for MASH cirrhosis, a condition with limited options. This could significantly impact patients suffering from advanced liver disease and portal hypertension, potentially reducing life-threatening complications. For investors, these nuanced results suggest a path forward, but also highlight the challenges of drug development in complex diseases, placing GALT in a competitive landscape with other biotechs vying for a share of the lucrative MASH market.

Risk Assessment

Risk Level: high — The NAVIGATE trial's primary composite endpoint did not reach statistical significance in the intent-to-treat population (N=355), indicating a higher risk of regulatory hurdles despite positive subgroup data. The company's proposed Phase 2 trial for head and neck cancer is also dependent on timing of financing, adding financial uncertainty.

Analyst Insight

Investors should closely monitor GALT's subsequent analyses and potential discussions with the FDA regarding the NAVIGATE trial's subgroup data. Given the financing dependency for the immuno-oncology program, investors should also assess the company's capital raising strategies and cash burn rate before making significant commitments.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Key Numbers

• $109 million — Aggregate market value of common equity held by non-affiliates (As of June 30, 2025)
• 65,827,448 — Shares outstanding of common stock (As of March 2, 2026)
• 357 — Patients randomized in NAVIGATE trial (Completed in February 2023)
• 43.2% — Reduced incidence of varices in belapectin 2 mg/kg dose group vs placebo (NAVIGATE ITT population (N=355))
• 49.3% — Reduced incidence of varices in belapectin 2 mg/kg dose group (NAVIGATE per-protocol population (n=287), p-value < 0.05)
• 68.1% — Significantly reduced incidence of varices in U.S. patients treated with belapectin 2 mg (NAVIGATE U.S. completer patients (n=186), p=0.02)

Key Players & Entities

• GALECTIN THERAPEUTICS INC. (company) — Registrant
• FDA (regulator) — U.S. Food and Drug Administration
• belapectin (company) — Lead galectin-3 inhibitor drug candidate
• NAVIGATE (company) — Phase 2b/3 clinical trial
• MASH (company) — Metabolic dysfunction-associated steatohepatitis
• Galectin Sciences LLC (company) — Majority-owned joint venture subsidiary
• Providence Portland Cancer Center (company) — Previous collaboration partner
• NASDAQ Stock Market (regulator) — Exchange where GALT Common Stock is registered

FAQ

Risk Factors

• Reliance on FDA Approval and Regulatory Pathways [high — regulatory]: The company's success is heavily dependent on obtaining regulatory approval from the FDA and other global health authorities for its drug candidates, particularly belapectin. The failure to demonstrate sufficient efficacy or safety in ongoing or future clinical trials, such as the NAVIGATE trial's ITT population, could prevent regulatory approval and commercialization.
• Need for Additional Financing [high — financial]: Galectin Therapeutics Inc. has a history of operating losses and requires substantial funding to support its ongoing clinical development programs, including the planned Phase 2 trial for head and neck cancer. The company's ability to continue as a going concern is contingent upon its ability to secure additional financing through equity offerings, debt financing, or strategic partnerships.
• Competition in MASH and Cancer Markets [medium — market]: The markets for treating MASH cirrhosis and head and neck cancer are highly competitive, with numerous pharmaceutical companies developing novel therapies. The company faces competition from established players and emerging biotechs, which could impact market penetration and pricing if belapectin receives approval.
• Clinical Trial Execution and Patient Recruitment [medium — operational]: The company's ability to successfully execute clinical trials, such as the NAVIGATE trial which randomized 357 patients, is critical. Delays in patient recruitment, unexpected adverse events, or failure to meet trial endpoints can significantly impact development timelines and costs.
• Burn Rate and Cash Runway [medium — financial]: As a clinical-stage biopharmaceutical company, Galectin Therapeutics has a significant operating expense base related to research and development. The company's cash position and burn rate are critical factors determining its ability to fund operations and clinical trials until profitability or further financing is secured.

Industry Context

Galectin Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on developing therapies for fibrotic diseases and cancer. The MASH market is rapidly evolving with significant unmet needs, attracting substantial investment and numerous drug candidates. Similarly, the oncology space, particularly for head and neck cancer, is characterized by advancements in immunotherapy and combination treatments.

Regulatory Implications

The company's future hinges on successful navigation of stringent regulatory pathways, primarily with the FDA. Positive results in specific patient subgroups, like the U.S. completers in the NAVIGATE trial, may be crucial for discussions with regulators, but failure to meet primary endpoints in broader populations presents significant hurdles for approval.

What Investors Should Do

1. Monitor financing activities closely.
2. Evaluate biomarker and subgroup data for belapectin.
3. Assess competitive landscape in MASH and oncology.

Key Dates

• 2023-02-01: Completion of Randomizations in NAVIGATE Trial — The company completed randomization of 357 patients in its Phase 2b/3 NAVIGATE trial evaluating belapectin for MASH cirrhosis, a key milestone in its development program.
• 2024-12-01: Announcement of NAVIGATE Trial Top-Line Results — Top-line results for the NAVIGATE trial were reported, showing mixed outcomes on the primary endpoint but positive signals in specific patient populations and biomarker data, influencing future development and financing strategies.

Glossary

MASH

Metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis (NASH). It is a severe form of fatty liver disease characterized by inflammation and liver cell damage. (Galectin Therapeutics is developing belapectin for MASH cirrhosis, a key indication for the company.)

Esophageal Varices

Swollen veins in the esophagus, often caused by portal hypertension, which can lead to life-threatening bleeding. (The prevention of esophageal varices was the primary endpoint of the NAVIGATE trial for belapectin.)

Galectin-3

A protein that plays a role in various biological processes, including fibrosis, immune cell function, and cell growth. It is implicated in the pathogenesis of fibrotic diseases. (Belapectin, the company's lead drug candidate, is designed to inhibit galectin-3.)

Intent-to-Treat (ITT) Population

A principle in clinical trial analysis where all randomized subjects are included in the statistical analysis according to the group to which they were assigned, regardless of whether they received the treatment. (The NAVIGATE trial's primary endpoint was evaluated in the ITT population (N=355), where statistical significance was not met.)

Per-Protocol Population (PPP)

A subset of trial participants who adhered to the study protocol throughout the trial, excluding those who deviated significantly. (In the NAVIGATE trial, the 2 mg/kg dose of belapectin showed a statistically significant reduction in varices incidence in the PPP (n=287).)

Liver Stiffness Measurement (LSM)

A non-invasive method, often using transient elastography, to assess the degree of fibrosis in the liver. (Belapectin demonstrated reduced liver stiffness in biomarker analyses from the NAVIGATE trial, indicating potential anti-fibrotic effects.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue, margins, and asset/debt levels, is not available within the provided text excerpt of the 10-K filing. The excerpt focuses on the business overview, risk factors, and summary of key trial results.

Key Financial Figures

• $0.001 — ge on which registered Common Stock, $0.001 Par Value Per Share GALT The NASDAQ

Filing Documents

• ef20060823_10k.htm (10-K) — 1851KB
• ef20060823_ex21-1.htm (EX-21.1) — 4KB
• ef20060823_ex23-1.htm (EX-23.1) — 4KB
• ef20060823_ex31-1.htm (EX-31.1) — 10KB
• ef20060823_ex31-2.htm (EX-31.2) — 10KB
• ef20060823_ex32-1.htm (EX-32.1) — 5KB
• ef20060823_ex32-2.htm (EX-32.2) — 5KB
• 0001140361-26-012155.txt (&nbsp;) — 8584KB
• galt-20251231.xsd (EX-101.SCH) — 65KB
• galt-20251231_def.xml (EX-101.DEF) — 360KB
• galt-20251231_lab.xml (EX-101.LAB) — 670KB
• galt-20251231_pre.xml (EX-101.PRE) — 387KB
• galt-20251231_cal.xml (EX-101.CAL) — 41KB
• ef20060823_10k_htm.xml (XML) — 1059KB

Business

Business 1 ITEM 1A.

Risk Factors

Risk Factors 17 ITEM 1B. Unresolved Staff Comments 36 ITEM IC Cybersecurity 36 ITEM 2.

Properties

Properties 37 ITEM 3.

Legal Proceedings

Legal Proceedings 37 ITEM 4. Mine Safety Disclosure 37 PART II ITEM 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 38 ITEM 6. [Reserved] 38 ITEM 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 38 ITEM 7A. Quantitative and Qualitative Discussions About Market Risk 46 ITEM 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 47 ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 47 ITEM 9A.

Controls and Procedures

Controls and Procedures 47 ITEM 9B. Other Information 49 ITEM 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 49 PART III ITEM 10. Directors, Executive Officers and Corporate Governance 50 ITEM 11.

Executive Compensation

Executive Compensation 56 ITEM 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 69 ITEM 13. Certain Relationships, Related Transactions and Director Independence 72 ITEM 14. Principal Accountant Fees and Services 75 PART IV ITEM 15. Exhibits and Financial Statement Schedules 76 ITEM 16 Form 10-K Summary 80

SIGNATURES

SIGNATURES 81 1 Index PART I Item 1.

Business

Business Overview We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary, patented complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique carbohydrate-based candidate compounds that largely bind and inhibit galectin proteins, particularly galectin-3, we are undertaking the focused pursuit of therapies for indications where galectin proteins have a demonstrated role in the pathogenesis of a given disease. We focus on diseases with serious, life-threatening consequences and those where current treatment options are limited specifically in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and certain cancer indications. Our strategy is to establish and implement clinical development programs that add value to our business in the shortest period of time possible and to seek strategic partners when one of our programs becomes advanced and requires significant additional resources. Our lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. Belapectin has the potential to treat many diseases due to galectin-3's involvement in multiple key biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell grow

View Full Filing

View this 10-K filing on SEC EDGAR